In Brief: Aspirin professional labeling
This article was originally published in The Tan Sheet
Aspirin professional labeling: Aspirin Foundation of America, in a recent letter to FDA, expresses support for the agency's June 13 proposal to add an indication for the reduction of the risk of vascular mortality in patients with a suspected acute myocardial infarction in aspirin professional labeling ("The Tan Sheet" June 17, p. 3). The group also urges FDA to add the treatment of acute MI to the professional labeling section of the monograph for aspirin...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC